ProNAi Therapeutics, Inc., a Plymouth, MI-based developer of nucleic acid therapeutics, closed a $12m Series C financing round.
The round was led by Capital Midwest Fund and includes existing and new investors.
Founded in 2004 and led by Mina Sooch, CEO, ProNAi Therapeutics is working to discover and develop new drugs to treat cancer and other genetically defined diseases with its proprietary DNA interference (DNAi®) technology. Its lead compound, PNT2258, is in Phase II trials against BCL2-driven lymphomas with a pipeline of DNAi leads for over 30 cancer and non-cancer targets, including CMYC and KRAS.
The company intends to use the funds to expand cancer studies for PNT2258 in defined Lymphoma patients.